Status:
COMPLETED
To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
20-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess safety, tolerability and pharmacokinetics after a single and repeated oral doses of TC-5214 (S-mecamylamine) in healthy male Japanese subjects.
Eligibility Criteria
Inclusion
- Japanese Healthy male ≥20 and ≤55 years old inclusive with suitable veins for cannulation or repeated venipuncture
- Have a body mass index (BMI) of ≥18 and ≤27 kg/m2 and weigh at least 50 kg
Exclusion
- History of any clinically significant medical or neurologic disease or disorder which, in the opinion of the investigator and sponsor, may either put the subject at risk because of participation in the study, or influence the results of the subject's
- History of psychiatric disorders
- Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01175564
Start Date
July 1 2010
End Date
September 1 2010
Last Update
February 6 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.